Antibodies That Can Protect Against Identification of Kovid-19

Antibodies That Can Protect Against Identification of Kovid-19

Let’s Start this Interesting Article Shared on

BOSTON: Scientists have identified a human antibody that says it can potentially prevent or limit the SARS-CoV-2 infection that causes Kovid-19 disease.
Researchers at the University of Massachusetts Medical School (UMMS) in the US discovered a cross-reactive human monoclonal antibody (MAB) of the SARS-CoV-2 spike protein that blocks ACE2 receptor binding on mucosal tissue of the respiratory tract. .
The origins of this rapid and important discovery go back 16 years, when UMMS researchers developed an IgG monoclonal antibody that was effective against a similar virus, SARS, according to a study published in the journal Nature Communications.
When SARS-CoV-2 was identified and started to spread, researchers realized that the first MAB could help with this new infection.
He began the process of reviving the old SARS program, retrieving frozen cells that had been developed 16 years earlier, melting them and determining whether one novel worked for the coronovirus would work for another .
Although there was a 90 percent similarity between the two coronavir, the monoclonal antibody showed no binding to the current coronavirus, the researchers said.
The team drew on their experience with a separate research program to develop “secretory IgAs (sIgA),” antibodies that play an important role in immunity to mucosal surfaces.
The approach worked, producing an antibody with binding affinity and neutralization activity.
This antibody was designated MAb362.
“We were excited to learn that antibodies to SARS-CoV-2 are more effective in binding and neutralizing viruses when they are in the sIgA isotype of the antibody than normally circulating IgG antibodies,” Mark Klempner, a professor Medication in UMMS.
“In nature, sIgA antibodies coat the mucosal surfaces, like respiration, gastrointestinal infection (GI) and GU tracts, where they are stabilized by the mucous layer on these surfaces. There, they prevent a pathogen for host cells. Do important work., Thus preventing infection, “Kleppner said.
Based on these results, the team worked with Celia Schiffer, a professor of biochemistry and her then graduate student Shurong Hou, to see if they could understand the nature of the effect of IgA antibodies.
They found that MAb362 shares a similar structure with MAb 80R, another SARS antibody with a crystal structure in complex with SARS-CoV.
A molecular model revealed a highly conserved protective epitope within the receptor-binding domain of the S protein. Researchers found that MAb362 S neutralizes the SAR-CoV-2 virus by ejecting the S protein directly to HACE2 receptors.
“So our discovery — which began during a coffee break interaction, resulted in a unique IgA antibody that could possibly be applied via mucosal administration, in combination with other systematically administered therapeutics for direct mucosal protection, “Kleiner said.


Leave a Reply

Your email address will not be published. Required fields are marked *